10x Genomics, Inc. · NASDAQ:TXG
10x Genomics — Q1 2026 Earnings Presentation
7 slides from 10x Genomics's earnings presentation, May 7, 2026
Slide 1: Q1 2026 Earnings Call Prepared Remarks
Q1 2026 Earnings Call Prepared Remarks May 7, 2026 Cassie Corneau Senior Director, Head of Investor Relations and Strategic Finance Thank you and good afternoon, everyone. Earlier today, 10x Genomics released financial results for the first quarter ended March 31, 2026. If you have not received this
Slide 2: Why we built Atera
response from researchers and the broader scientific community, and what we have heard so far has been extraordinary. Before I talk about what Atera is and what it does, I want to spend a moment on why we built it. The central challenge of biology is that it is very complex. It is complex in just ab
Slide 3: Atera platform roadmap and early customer response
We built Atera to be a long-duration, upgradeable platform, and we intend to continue delivering new capabilities over the years ahead. The roadmap on the platform includes workflow automation designed to enable true sample-in, data-out capability, protein multiomics, in situ sequencing for spatial
Slide 4: Adam Taich
Building on another theme that has become increasingly prominent in our business, we are seeing growing interest in translational applications across both academia and biopharma. Customers are increasingly focused on identifying human-relevant drug targets and, critically, biomarkers of response for
Slide 5: Consumables and instrument revenue, gross margin
Total consumables revenue was up 13%, with growth in both Single Cell and Spatial. Single Cell consumables revenue was up 6%, supported by double-digit growth in reaction volumes, and Flex continued to be the most popular assay by volume in the quarter. Spatial consumables continued to perform well
Slide 6: Serge Saxonov
Serge Saxonov Chief Executive Officer, Co-founder Thanks, Adam. Before we open it up for questions, I want to pick up on Adam’s earlier remarks and reflect on how much difference a year makes. While our internal conviction never wavered, the external circumstances a year ago put incredible pressure
Slide 7: Forward Looking Statements
Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, whic